Anticardiolipin antibodies in hemodialysis patients with hepatitis C and their role in fistula failure

Basit Öğe Kaydı
dc.contributor.authorOzmen, S.
dc.contributor.authorDanis, R.
dc.contributor.authorAkin, D.
dc.contributor.authorBatun, S.
dc.date.accessioned2024-04-24T17:18:50Z
dc.date.available2024-04-24T17:18:50Z
dc.date.issued2009
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground/Aims: Several conflicting results are presently reported regarding raised IgG and IgM-anticardiolipin antibodies (ACA) titers in hemodialysis (HD) patients and their role in vascular access dys-function. We aimed to determine the prevalence of both IgM and IgG-ACA titers and to analyze retrospectively their role in primary and secondary arteriovenous fistula (AVF) failure in a homogeneous group of HD patients with chronic hepatitis C. Methods: This study included 103 adults on maintenance hemodialysis with chronic hepatitis C infection. All participants had blood samples drawn predialysis and after an overnight fast. Analysis included biochemistry, IgG and IgM ACA, Anti-HCV, HBsAg, serum HCV RNA and HCV genotyping. Results: The prevalence of IgG-ACA was 14.6% (15/103). No patient had a positive value of the IgM-ACA test. HCV replication was detected in 52 of 76 patients. The most common HCV genotype was genotype 1 (90%). The percentage of females was higher in ACA(+) group (p = 0.038). There were no significant differences between subjects with and without ACA-IgG regarding other parameters studied. No difference in regard to AVF survival was detected between ACA(+) and ACA(-) groups (p > 0.05). Conclusion: We found no significant differences in primary or secondary AVF failure between patients with elevated and normal ACA. Therefore, we conclude that AVFF may be caused by factors other than ACA in these patients. More prospective studies are needed to confirm this observation.en_US
dc.identifier.doi10.2379/CNX06218
dc.identifier.endpage198en_US
dc.identifier.issn0301-0430
dc.identifier.issue3en_US
dc.identifier.pmid19761724
dc.identifier.scopus2-s2.0-70350164190
dc.identifier.scopusqualityQ3
dc.identifier.startpage193en_US
dc.identifier.urihttps://doi.org/10.2379/CNX06218
dc.identifier.urihttps://hdl.handle.net/11468/18924
dc.identifier.volume72en_US
dc.identifier.wosWOS:000271167100006
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherDustri-Verlag Dr Karl Feistleen_US
dc.relation.ispartofClinical Nephrology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnticardiolipin Antibodiesen_US
dc.subjectHemodialysisen_US
dc.subjectVascular Access Failureen_US
dc.titleAnticardiolipin antibodies in hemodialysis patients with hepatitis C and their role in fistula failureen_US
dc.titleAnticardiolipin antibodies in hemodialysis patients with hepatitis C and their role in fistula failure
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu